Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Thu, Jul 9, 2026

1 updates

8:30 AM

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

tevapharm.com

Tue, Jul 7, 2026

1 updates

7:00 AM

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

tevapharm.com

Thu, Jun 18, 2026

4 updates

5:00 PM

Teva Releases Q2 2026 Aide Memoire

tevapharm.com

4:56 PM

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

tevapharm.com

4:56 PM

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

tevapharm.com

4:30 PM

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

tevapharm.com

Wed, Jun 10, 2026

1 updates

12:03 PM

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

tevapharm.com

Mon, Jun 8, 2026

1 updates

8:00 AM

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

tevapharm.com

Fri, Jun 5, 2026

1 updates

11:30 AM

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

tevapharm.com

Thu, Jun 4, 2026

1 updates

8:30 AM

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

tevapharm.com

Mon, Jun 1, 2026

1 updates

4:30 PM

Teva to Present at the Goldman Sachs Global Healthcare Conference

tevapharm.com

Thu, May 21, 2026

1 updates

12:30 PM

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

tevapharm.com

Mon, May 18, 2026

2 updates

8:30 AM

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

tevapharm.com

8:00 AM

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

tevapharm.com

Mon, May 4, 2026

1 updates

4:30 PM

Teva to Present at the BofA Securities Health Care Conference

tevapharm.com

Thu, Apr 30, 2026

1 updates

8:30 AM

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

tevapharm.com

Wed, Apr 29, 2026

2 updates

7:00 AM

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

tevapharm.com

6:30 AM

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

tevapharm.com

Wed, Apr 15, 2026

1 updates

8:00 AM

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

tevapharm.com

Tue, Apr 14, 2026

1 updates

8:00 AM

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

tevapharm.com